Eisele Jeffrey 4
4 · Apellis Pharmaceuticals, Inc. · Filed Jan 31, 2023
Insider Transaction Report
Form 4
Eisele Jeffrey
Chief Development Officer
Transactions
- Sale
Common Stock
2023-01-30$52.76/sh−883$46,587→ 46,468 total
Footnotes (1)
- [F1]Sale originated from established 10b5-1 trading plan.